Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts

International Journal of Oncology

Volumn 38, Issue 1, 2011, Pages 71-80

  Ackermann, Maximilian ^a   Carvajal, Irvith M ^b   Morse, Brent A ^b   Moreta, Miguel ^b   O'Neil, Steven ^b   Kossodo, Sylvie ^c   Peterson, Jeffrey D ^c   Delventhal, Vera ^a   Marsh, H Nicholas ^b   Furfine, Eric S ^b   Konerding, Moritz A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c VisEn Medical Inc   (United States)

Author keywords

Adnectin; Antiangiogenesis; Corrosion casting; Fluorescence molecular tomography; Tumor microvasculature; Xenograft

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CT 322; FIBRONECTIN; PEGYLATED ADNECTIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; FIBRONECTINS; HUMANS; KIDNEY; MICE; MICE, NUDE; MICROSCOPY, ELECTRON, SCANNING; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650804397     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo-00000825     Document Type: Article

References (40)

1. Dvorak HF, Brown LF, Detmar M and Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
2. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
3. Benjamin LE, Golijanin D, Itin A, Pode D and Keshet E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103: 159-165, 1999. (Pubitemid 29053133)
4. Konerding MA, Fait E, Dimitropoulou C, et al: Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. Am J Pathol 152: 1607-1616, 1998.
5. Mancuso MR, Davis R, Norberg SM, et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116: 2610-2621, 2006.
6. Ruoslahti E: Specialization of tumour vasculature. Nat Rev Cancer 2: 83-90, 2002.
7. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
8. Verheul HM and Pinedo HM: Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7: 475-485, 2007.
9. Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62, 2005.
10. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312: 1171-1175, 2006.
11. Blagosklonny MV: How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 4: 1307-1310, 2005.
12. Ma J and Waxman DJ: Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 7: 3670-3684, 2008.
13. Koide A, Bailey CW, Huang X and Koide S: The fibronectin type III domain as a scaffold for novel binding proteins. J Mol Biol 284: 1141-1151, 1998. (Pubitemid 28558562)
14. Xu L, Aha P, Gu K, Kuimelis RG, Kurtz M, Lam T, et al: Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 9: 933-942, 2002.
15. Parker MH, Chen Y, Danehy F, Dufu K, Ekstrom J, Getmanova E, Gokemeijer J, Xu L and Lipovsek D: Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 18: 435-444, 2005.
16. Getmanova EV, Chen Y, Bloom L, Gokemeijer J, Shamah S, Warikoo V, et al: Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by direct protein evolution in vitro. Chem Biol 16: 549-556, 2006.
17. Dineen SP, Sullivan LA, Beck AW, et al: The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8: 352, 2008.
18. Mamluk R, Carvajal I, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim A-I, Gokemeijer J, Storek M, et al: Anti-tumor of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. mAbs 2: 199-208, 2010.
19. Weibel ER: Morphometry of the human lung: the state of the art after two decades. Bull Eur Physiopathol Respir 15: 999-1013, 1979.
20. Zachary I: VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem Soc Trans 31: 1171-1177, 2003.
21. Alitalo K and Carmeliet P: Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1: 219-227, 2002. (Pubitemid 41039145)
22. Duff SE, Li C, Jeziorska M, et al: Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89: 426-430, 2003.
23. Duff SE, Jeziorska M, Kumar S, et al: Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis 9: 793-800, 2007.
24. Liang WC, Wu X, Peale FV, et al: Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281: 951-961, 2006.
25. Gerber HP, Kowalski J, Sherman D, Eberhard DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60: 6253-6258, 2000.
26. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005.
27. Drevs J, Müller-Driver R, Wittig C, et al: PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022, 2002.
28. Drevs J, Konerding MA, Wolloscheck T, et al: The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347-354, 2004.
29. Wildiers H, Guetens G, De Boeck G, et al: Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 88: 1979-1986, 2003.
30. Verheul HM, Hammers H, van Erp K, et al: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 13: 4201-4208, 2007. (Pubitemid 47105984)
31. Pries AR, Cornelissen AJ, Sloot AA, et al: Structural adaptation and heterogeneity of normal and tumor microvascular networks. PLoS Comput Biol 5: e1000394, 2009.
32. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988.
33. 2 extraction is a key parameter determining the oxygenation status of malignant tumors and normal tissues. Int J Oncol 22: 795-798, 2003.
34. Jain RK, Tong RT and Munn LL: Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67: 2729-2735, 2007.
35. Duda DG, Jain RK and Willett CG: Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25: 4033-4042, 2007.
36. Huber PE, Bischof M, Jenne J, et al: Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65: 3643-3655, 2005.
37. Dickson PV, Hammer JB, Sims TL, Fraga CH, et al: Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systematically administered chemotherapy. Clin Cancer Res 13: 3942-3950, 2007.
38. Dings RPM, Loren M, Heun H, McNiel E, et al: Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13: 3395-3402, 2007.
39. Montet X, Ntziachristos V, Grimm J and Weissleder R: Tomographic fluorescence mapping of tumor targets. Cancer Res 65: 6330-6336, 2005.
40. Montet X, Figueiredo JL, Alencar H, Ntziachristos V, Mahmood U and Weissleder R: Tomographic fluorescence imaging of tumor vascular volume in mice. Radiology 242: 751-758, 2007. (Pubitemid 46310087)